PET is more than a foundation on which to build a hybrid technology. In its basic form, it continues to provide excellent spatial and temporal resolution for clinicians in cardiology, neurology, and oncology. Once deemed expensive, now PET is often considered a cost-effective option in the molecular imaging realm.

The Secretary of Energy, Steven Chu, recognizes Positron/MIT who have accomplished outstanding work in transferring technology developed in the Federal Laboratory to the commercial marketplace.

View Award Letter

Positron Corporation posts—PosiRx™:  Introduction Video—to their corporate website.

PosiRx™ is the first device of its kind to offer an automated solution for on-site radiopharmaceutical dose preparation and delivery. 

PosiRx™—A “Virtual Nuclear Pharmacy,” is empowering cardiac care!

To view, visit our website... Read More

The possibility of quantifying myocardial blood flow (MBF) with PET has existed for decades, but its clinical use has been limited. MBF is assessed more often in relative terms, with visible differences in flow between regions of myocardium, used as an indicator of problems. Now, new developments in tracers could... Read More

Rockville, MD - The US Food and Drug Administration (FDA) is notifying physicians that CardioGen-82 (Bracco Diagnostics), a generator used at clinical sites to produce the rubidium (Rb)-82 chloride injection used for cardiac positron-emission-tomography (PET) scans, will be returning to market [1].

For its return,... Read More

Bracco resumed shipping generators to some customers yesterday providing stability to the Cardiac PET market.  New information on Bracco's website pertaining to labeling and quality control can be found at:  http://www.cardiogen.com/cardiogen-82/prescribing-information.html